Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 35 |
| Active Pipeline (Recruiting Now) | 19 (15) |
| Completed vs Stopped Early | 10 / 3 (8.6%) |
| Median Closed Actual Enrollment | 85 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| UZ Leuven | Leuven, Flemish Brabant | 14 |
| UZ Gent | Ghent | 4 |
| UZ Brussel | Brussels | 3 |
Explore interactive annual charts and M&A subsidiary rollups in the Universitaire Ziekenhuizen KU Leuven Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.